[Age- and weight-related dosage of dDAVP in the treatment of primary nocturnal enuresis].
BACKGROUND
In treating primary nocturnal enuresis the dosages recommended for an intranasal application of dDAVP are 20, 30 or 40 microgram depending on the response. Dosages that take the patient's weight or age into account are not commonly used until now.


METHODS
In the present prospective study including 43 children therapeutic success was therefore evaluated on the basis of the dosage that was standardized according to both age and weight of the patients. The patients' weight ranged from 16.5 to 98 kg, their age from 6 to 14.9 years.


RESULTS
The dDAVP dosages that were applied ranged from 0.3 and 2.4 microgram/kg and 3.74 and 15.3 microgram x age/kg respectively. Therapeutic efficacy was at 63 %.


CONCLUSIONS
The results suggest an ideal weight-related dosage of 1 microgram x weight or rather an age- and weight-related dosage of 8 microgram x weight/age. A higher dosage evidently is of little use since there was a significant difference between the non-responders and the responders (p < 0.01) with the non-responders not even reacting to higher dosages.
Eggert
P
P
Klinik für Allgemeine Pädiatrie der Christian-Albrechts-Universität Kiel, Germany. p.egggert@pediatrics.uni-kiel.de
Chavez-Kattau
K
K
Müller
D
D
D000281:Administration, Intranasal; D000293:Adolescent; D000367:Age Factors; D001835:Body Weight; D002648:Child; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004775:Enuresis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D011446:Prospective Studies; D016896:Treatment Outcome; D014563:Urodynamics / Q000187:drug effects
D003894:Deamino Arginine Vasopressin